A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients

Carlyn Rose Tan; Noel Estrada-Merly; Heather Landau; Lazaros Lekakis; Rahul Banerjee; Hira Mian; Saad Z. Usmani; Amr Hanbali; Hillard M. Lazarus; Robert A. Kyle; Bhagirathbhai Dholaria; Susan Bal; Christopher Strouse; Hemant S. Murthy; Baldeep Wirk; Taiga Nishihori; Shaji Kumar; Nina Shah; Muzaffar Qazilbash; Anita D’Souza

doi:10.1038/s41409-021-01527-z

A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients

Carlyn Rose Tan
, Noel Estrada-Merly
, Heather Landau
, Lazaros Lekakis
, Rahul Banerjee
, Hira Mian
, Saad Z. Usmani
, Amr Hanbali
, Hillard M. Lazarus
, Robert A. Kyle
, Bhagirathbhai Dholaria
, Susan Bal
, Christopher Strouse
, Hemant S. Murthy
, Baldeep Wirk
, Taiga Nishihori
, Shaji Kumar
, Nina Shah
, Muzaffar Qazilbash
, Anita D’Souza

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	295-298
Number of pages	4
Journal	Bone Marrow Transplantation
Volume	57
Issue number	2
DOIs	https://doi.org/10.1038/s41409-021-01527-z
State	Published - Feb 2022

All Science Journal Classification (ASJC) codes

Hematology
Transplantation

Access to Document

10.1038/s41409-021-01527-z

Cite this

Tan, C. R., Estrada-Merly, N., Landau, H., Lekakis, L., Banerjee, R., Mian, H., Usmani, S. Z., Hanbali, A., Lazarus, H. M., Kyle, R. A., Dholaria, B., Bal, S., Strouse, C., Murthy, H. S., Wirk, B., Nishihori, T., Kumar, S., Shah, N., Qazilbash, M., & D’Souza, A. (2022). A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients. Bone Marrow Transplantation, 57(2), 295-298. https://doi.org/10.1038/s41409-021-01527-z

@article{6a83d6465788435fba21dd3d7c8a900f,

title = "A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients",

author = "Tan, \{Carlyn Rose\} and Noel Estrada-Merly and Heather Landau and Lazaros Lekakis and Rahul Banerjee and Hira Mian and Usmani, \{Saad Z.\} and Amr Hanbali and Lazarus, \{Hillard M.\} and Kyle, \{Robert A.\} and Bhagirathbhai Dholaria and Susan Bal and Christopher Strouse and Murthy, \{Hemant S.\} and Baldeep Wirk and Taiga Nishihori and Shaji Kumar and Nina Shah and Muzaffar Qazilbash and Anita D{\textquoteright}Souza",

note = "Funding Information: The research reported in this publication was supported by K23 HL141445 (AD). The CIBMTR is supported primarily by Public Health Service U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); HHSH250201700006C from the Health Resources and Services Administration (HRSA); and N00014-20-1-2705 and N00014-20-1-2832 from the Office of Naval Research; support is also provided by Be the Match Foundation, the Medical College of Wisconsin, the National Marrow Donor Program, and from the following commercial entities: AbbVie; Actinium Pharmaceuticals, Inc.; Adaptive Biotechnologies Corporation; Adienne SA; Allovir, Inc.; Amgen, Inc.; Angiocrine Bioscience; Astellas Pharma US; Bluebird Bio, Inc.; Bristol Myers Squibb Co.; CSL Behring; CytoSen Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Eurofins Viracor; ExcellThera; Fate Therapeutics; Gamida-Cell, Ltd.; Genentech Inc; GlaxoSmithKline; Incyte Corporation; Janssen/Johnson \& Johnson; Jasper Therapeutics; Jazz Pharmaceuticals, Inc.; Karyopharm Therapeutics; Kiadis Pharma; Kite, a Gilead Company; Kyowa Kirin; Legend Biotech; Magenta Therapeutics; Medac GmbH; Merck \& Co.; Millennium, the Takeda Oncology Co.; Miltenyi Biotec, Inc.; MorphoSys; Novartis Pharmaceuticals Corporation; Omeros Corporation; Oncoimmune, Inc.; Orca Biosystems, Inc.; Pfizer, Inc.; Pharmacyclics, LLC; Sanofi Genzyme; Seagen, Inc.; Stemcyte; Takeda Pharmaceuticals; Tscan; Vertex; Vor Biopharma; Xenikos BV. Funding Information: Dr. Dholaria reports institutional research support from Takeda, Janssen, Angiocrine, Pfizer, Poseida. {\'U}dvisory board for Jazz. Dr. Banerjee reports grants from Pack Health, personal fees from SparkCures, outside the submitted work. Dr. Mian reports grants from Janssen and consulting fees from Janssen, BMS, Takeda, Sanofi, Amgen, GSK. Personal fees from Amgen, Sanofi, BMS/Celgene, Janssen. Board of directors for Myeloma Canada. Dr. Tan reports other financial interests—spouse employed by Janssen R\&D. Dr. Usmani reports grants and personal fees from Amgen, personal fees from Abbvie, grants from BMS, grants and personal fees from Celgene, personal fees from MundiPharma, grants from Pharmacyclics, grants and personal fees from Sanofi, grants and personal fees from Seattle Genetics, grants and personal fees from Janssen, grants and personal fees from Takeda, grants and personal fees from SkylineDX, grants and personal fees from Merck, grants and personal fees from GSK, outside the submitted work. Dr. Murthy reports board participation for CRISPR Therapeutics. Dr. Qazilbash reports data safety board participation for Autolus and the advisory board for Oncopeptides. Dr. Dholaria reports institutional research funds from Janssen, Poseida, Angiocrine, Takeda. Personal advisory funds from Jazz. Dr. Kumar reports institutional research support for clinical trials from Abbvie, Celgene, Janssen, Takeda, Adaptive, KITE, Medimmune/Astra Zeneca, Merck, Novartis, Roche, and Sanofi. Advisory board participation paid to the institution from Abbvie, Celgene, Janssen, Takeda, Adaptive, KITE, and Medimmune/Astra Zeneca and Oncopeptides independent review committee. Dr. Nishihori reports research support outside of the submitted work paid to the institution from Norvartis and Karyopharm. Dr. Strouse reports consulting fees from Bristol Meyer Squibb. Dr. Landau reports grant support from Takeda Pharmaceuticals, payment or honoraria from Genzyme corporation. Participation on board for Janssen, Genzyme, Celgene. Dr. D{\textquoteright}Souza reports grant support from Takeda, TeneoBio, Sanofi, Caelum and Prothena, consulting fees from Janssen, and advisory board participation fees from Imbrium, Pfizer and BMS.",

year = "2022",

month = feb,

doi = "10.1038/s41409-021-01527-z",

language = "English (US)",

volume = "57",

pages = "295--298",

journal = "Bone Marrow Transplantation",

issn = "0268-3369",

publisher = "Springer Nature",

number = "2",

}

Tan, CR, Estrada-Merly, N, Landau, H, Lekakis, L, Banerjee, R, Mian, H, Usmani, SZ, Hanbali, A, Lazarus, HM, Kyle, RA, Dholaria, B, Bal, S, Strouse, C, Murthy, HS, Wirk, B, Nishihori, T, Kumar, S, Shah, N, Qazilbash, M & D’Souza, A 2022, 'A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients', Bone Marrow Transplantation, vol. 57, no. 2, pp. 295-298. https://doi.org/10.1038/s41409-021-01527-z

TY - JOUR

T1 - A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients

AU - Tan, Carlyn Rose

AU - Estrada-Merly, Noel

AU - Landau, Heather

AU - Lekakis, Lazaros

AU - Banerjee, Rahul

AU - Mian, Hira

AU - Usmani, Saad Z.

AU - Hanbali, Amr

AU - Lazarus, Hillard M.

AU - Kyle, Robert A.

AU - Dholaria, Bhagirathbhai

AU - Bal, Susan

AU - Strouse, Christopher

AU - Murthy, Hemant S.

AU - Wirk, Baldeep

AU - Nishihori, Taiga

AU - Kumar, Shaji

AU - Shah, Nina

AU - Qazilbash, Muzaffar

AU - D’Souza, Anita

N1 - Funding Information: The research reported in this publication was supported by K23 HL141445 (AD). The CIBMTR is supported primarily by Public Health Service U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); HHSH250201700006C from the Health Resources and Services Administration (HRSA); and N00014-20-1-2705 and N00014-20-1-2832 from the Office of Naval Research; support is also provided by Be the Match Foundation, the Medical College of Wisconsin, the National Marrow Donor Program, and from the following commercial entities: AbbVie; Actinium Pharmaceuticals, Inc.; Adaptive Biotechnologies Corporation; Adienne SA; Allovir, Inc.; Amgen, Inc.; Angiocrine Bioscience; Astellas Pharma US; Bluebird Bio, Inc.; Bristol Myers Squibb Co.; CSL Behring; CytoSen Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Eurofins Viracor; ExcellThera; Fate Therapeutics; Gamida-Cell, Ltd.; Genentech Inc; GlaxoSmithKline; Incyte Corporation; Janssen/Johnson & Johnson; Jasper Therapeutics; Jazz Pharmaceuticals, Inc.; Karyopharm Therapeutics; Kiadis Pharma; Kite, a Gilead Company; Kyowa Kirin; Legend Biotech; Magenta Therapeutics; Medac GmbH; Merck & Co.; Millennium, the Takeda Oncology Co.; Miltenyi Biotec, Inc.; MorphoSys; Novartis Pharmaceuticals Corporation; Omeros Corporation; Oncoimmune, Inc.; Orca Biosystems, Inc.; Pfizer, Inc.; Pharmacyclics, LLC; Sanofi Genzyme; Seagen, Inc.; Stemcyte; Takeda Pharmaceuticals; Tscan; Vertex; Vor Biopharma; Xenikos BV. Funding Information: Dr. Dholaria reports institutional research support from Takeda, Janssen, Angiocrine, Pfizer, Poseida. Údvisory board for Jazz. Dr. Banerjee reports grants from Pack Health, personal fees from SparkCures, outside the submitted work. Dr. Mian reports grants from Janssen and consulting fees from Janssen, BMS, Takeda, Sanofi, Amgen, GSK. Personal fees from Amgen, Sanofi, BMS/Celgene, Janssen. Board of directors for Myeloma Canada. Dr. Tan reports other financial interests—spouse employed by Janssen R&D. Dr. Usmani reports grants and personal fees from Amgen, personal fees from Abbvie, grants from BMS, grants and personal fees from Celgene, personal fees from MundiPharma, grants from Pharmacyclics, grants and personal fees from Sanofi, grants and personal fees from Seattle Genetics, grants and personal fees from Janssen, grants and personal fees from Takeda, grants and personal fees from SkylineDX, grants and personal fees from Merck, grants and personal fees from GSK, outside the submitted work. Dr. Murthy reports board participation for CRISPR Therapeutics. Dr. Qazilbash reports data safety board participation for Autolus and the advisory board for Oncopeptides. Dr. Dholaria reports institutional research funds from Janssen, Poseida, Angiocrine, Takeda. Personal advisory funds from Jazz. Dr. Kumar reports institutional research support for clinical trials from Abbvie, Celgene, Janssen, Takeda, Adaptive, KITE, Medimmune/Astra Zeneca, Merck, Novartis, Roche, and Sanofi. Advisory board participation paid to the institution from Abbvie, Celgene, Janssen, Takeda, Adaptive, KITE, and Medimmune/Astra Zeneca and Oncopeptides independent review committee. Dr. Nishihori reports research support outside of the submitted work paid to the institution from Norvartis and Karyopharm. Dr. Strouse reports consulting fees from Bristol Meyer Squibb. Dr. Landau reports grant support from Takeda Pharmaceuticals, payment or honoraria from Genzyme corporation. Participation on board for Janssen, Genzyme, Celgene. Dr. D’Souza reports grant support from Takeda, TeneoBio, Sanofi, Caelum and Prothena, consulting fees from Janssen, and advisory board participation fees from Imbrium, Pfizer and BMS.

PY - 2022/2

Y1 - 2022/2

UR - https://www.scopus.com/pages/publications/85119447622

UR - https://www.scopus.com/pages/publications/85119447622#tab=citedBy

U2 - 10.1038/s41409-021-01527-z

DO - 10.1038/s41409-021-01527-z

M3 - Letter

C2 - 34802047

AN - SCOPUS:85119447622

SN - 0268-3369

VL - 57

SP - 295

EP - 298

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

IS - 2

ER -

A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Cite this